FUJIFILM SIGNS DISTRIBUTION AGREEMENT WITH MAJOR RUSSIAN PHARMACEUTICAL COMPANY R-PHARM FOR MEDICAL DEVICES AND DIETARY SUPPLEMENTS IN RUSSIA

May 25, 2018

 

FUJIFILM Corporation (President: Kenji Sukeno) signed a distribution agreement today with a major Russian pharmaceutical company JSC “R-Pharm” (Chairman of the Board: Alexey Repik, “R-Pharm”) for the distribution of Fujifilm’s medical devices in Russia. The company also signed an agreement with the parent company of R-Pharm, LLC “R-PHARM HOLDING” (Representative: Alexey Repik, “R-Pharm Holding”) for the distribution of Fujifilm’s dietary supplements in Russia.

Through R-Pharm, which has a direct sales network in the vast Russian market and a strong relationship with major medical institutions, Fujifilm will begin sales of its X-ray diagnostic imaging devices and endoscopes this summer, further strengthening its medical device business in Russia. Starting this winter, Fujifilm will also begin selling its dietary supplements through R-Pharm Holding. The supplements include those designed for the purpose of preventing lifestyle diseases.

Russia has a population of approximately 140 million with an average life span of 72 years. The Russian government considers the enhancement and advancement of healthcare services to be an urgent issue in order to ensure that the people of Russia live long and healthy lives, as well as to maintain and expand the working-age population. The size of the Russian pharmaceutical and medical device market is currently approximately four trillion yen, approximately 1/3 the size of Japan, and is expected to see rapid growth in the coming years. There has also been a heightened interest in dietary supplements for the prevention of lifestyle-related diseases in Russia due to concerns about health risks caused by obesity.      

This distribution contract is a part of the comprehensive business cooperation agreed upon by Fujifilm and R-Pharm mainly in the area of healthcare in December 2016. Fujifilm has been selling its medical devices including X-ray diagnostic imaging devices in Russia, mainly in urban areas. Fujifilm will leverage R-Pharm’s network as a pharmaceutical company to distribute through the vast region of Russia. Fujifilm will supply its medical devices such as X-ray diagnostic imaging devices and endoscopes to R-Pharm. R-Pharm will import these products to Russia and conduct marketing, sales and service activities for these products in Russia.

With regards to dietary supplements, Fujifilm will conduct marketing and sales activities through R-Pharm group. Fujifilm will leverage the recognition that the R-Pharm Group has gained in Russia’s healthcare industry as well as the Group’s distribution channels including drugstores and pharmacies that it has cultivated through its pharmaceutical business.

Fujifilm will continue to accelerate its business in Russia in various areas with a focus on healthcare and will work to contribute to the resolution of issues in the healthcare area in Russia. 

<Summary of R-Pharm>

Company Name

JSC “R-Pharm”

Representative

Alexey Repik

Location

111B, Leninskiy Prospect Moscow, 119421, Russia

Establishment

2001

Sales Revenue

RUB 63 billion (2016) (approx. 110 billion yen)

Business Description

Research and development, manufacturing and marketing pharmaceuticals including for cancer, HIV, infectious diseases and rheumatoid arthritis, and selling medical diagnostic equipment. 

 

<Summary of R-Pharm Holding>

Company Name

LLC “R-PHARM HOLDING”

Representative

Alexey Repik

Location

111B, Leninskiy Prospect Moscow, 119421, Russia

Establishment

2017

Business Description

Activities of its holding company, project management, management consulting

For enquiries on information in this media release, contact:

Media Contact:

FUJIFILM Corporation
Corporate Communications Division
TEL :+81-3-6271-2000

Other:

FUJIFILM Corporation
Healthcare Business Development Office
TEL :+81 3-6271-1530